Our Pricing

Wegovy Starter Dose UK: Complete Clinical Guide to Beginning Treatment

The Wegovy starter dose UK is the essential first step for patients beginning semaglutide treatment for weight management. At Cured Pharmacy, we provide the complete Wegovy starter dose from £69.00 with transparent pricing shown before your free online consultation with our UK-registered prescribers. Every Wegovy treatment plan begins with the 0.25mg starter dose, designed to help your body gradually adjust to semaglutide whilst minimising common gastrointestinal side effects.

Understanding the Wegovy Starter Dose UK Protocol

The Wegovy starter dose UK follows a structured dose-escalation schedule approved by the MHRA and recommended by NICE guidelines. Treatment begins with 0.25mg once weekly for four weeks, allowing patients to build tolerance to semaglutide before progressing to higher therapeutic doses [1]. This gradual titration approach significantly reduces the incidence of nausea, vomiting, and diarrhoea compared to starting at higher doses.

Clinical data from the STEP trials demonstrated that proper dose escalation, beginning with the starter dose, led to better treatment adherence and fewer discontinuations due to side effects [2]. The starter pack contains four pre-filled injection pens, each delivering exactly 0.25mg of semaglutide in a single weekly dose. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), ensures every patient receives comprehensive guidance on injection technique and dose progression during their clinical assessment.

After completing the four-week starter phase, patients typically progress to 0.5mg weekly for another four weeks, then continue escalating every four weeks through 1mg, 1.7mg, and finally reaching the maintenance dose of 2.4mg. This entire escalation pathway is designed to optimise both efficacy and tolerability, with each step supported by robust trial evidence.

Wegovy Starter Dose UK Pricing and Availability at Cured Pharmacy

At Cured Pharmacy, the Wegovy starter dose UK is available from £69.00 representing competitive UK pricing for this essential first month of treatment. Unlike some providers who bundle costs or hide fees until after consultation, we display transparent pricing upfront so you can make informed decisions about your weight management journey. New patients can Save £20 off their first order using code Weightlossnew, bringing the starter dose to just £69.00.

Our pricing includes the complete four-week starter pack with all necessary injection pens, free delivery to any UK address, and unlimited support from our clinical team throughout your treatment. Every Wegovy prescription requires assessment by a UK-registered prescriber, which we provide at no additional charge through our streamlined online consultation process that takes under three minutes to complete.

Stock Availability and Delivery Timescales

Following the UK-wide Wegovy shortage that affected availability throughout 2023 and early 2024, supplies have now stabilised and the Wegovy starter dose UK is consistently available through Cured Pharmacy. We maintain dedicated stock allocations for new patients beginning treatment, ensuring starter doses remain accessible even during periods of high demand. Orders placed before 3pm on weekdays are typically dispatched the same day, with discreet next-day delivery as standard.

Clinical Efficacy of the Wegovy Starter Dose UK Regimen

Whilst the Wegovy starter dose UK itself is not the therapeutic dose for weight loss, it plays a critical role in treatment success. The STEP 1 trial, which enrolled 1,961 adults with obesity, showed that participants who completed the full dose-escalation protocol starting from 0.25mg achieved an average weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [3]. Importantly, participants who adhered to the starter dose schedule showed significantly lower discontinuation rates.

The starter dose allows your body to adapt to semaglutide's mechanism of action, which includes slowing gastric emptying and reducing appetite through GLP-1 receptor agonism. By week four of the starter dose, most patients report improved tolerance to the medication and begin experiencing early appetite suppression effects, even at this sub-therapeutic dose level. This early positive experience correlates with better long-term adherence to the full treatment programme.

Expected Outcomes During the Starter Phase

During the four-week Wegovy starter dose UK period, patients may experience modest weight loss of 1-3kg on average, though this is not the primary goal of this phase [4]. The starter dose primarily serves to establish tolerability and teach proper injection technique. Some patients report reduced food cravings and earlier satiety during meals, reflecting semaglutide's central appetite-suppressing effects. Clinically significant weight loss typically begins once patients reach the 1mg or higher doses in months two through four of treatment.

How to Use the Wegovy Starter Dose UK Injection Pens

Each Wegovy starter dose UK pen is pre-filled with exactly 0.25mg of semaglutide and designed for single use. Injections should be administered once weekly, on the same day each week, into the abdomen, thigh, or upper arm using the subcutaneous injection technique. The pen features a simple twist-and-click mechanism that requires no manual dose setting, reducing the risk of dosing errors common with multi-dose injection devices.

Before your first injection, our clinical team provides detailed written and video guidance on proper technique. The injection itself takes seconds to complete and uses an ultra-fine 32-gauge needle that most patients report as virtually painless. Rotate injection sites each week to prevent lipodystrophy and maintain consistent absorption. The used pen should be disposed of in a sharps container, which we can provide upon request at no additional cost.

Common Side Effects During the Wegovy Starter Dose UK Phase

The most frequently reported side effects during the Wegovy starter dose UK period are gastrointestinal in nature, including nausea (reported by approximately 20% of patients), mild diarrhoea, constipation, and occasional abdominal discomfort [5]. These effects are typically mild to moderate and tend to diminish as your body adjusts to semaglutide. The low 0.25mg starter dose is specifically designed to minimise these reactions compared to starting at higher doses.

To reduce gastrointestinal side effects, our prescribers recommend eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated throughout the starter phase. Most patients find that any nausea peaks 1-3 days after their weekly injection and resolves before the next dose. Persistent or severe side effects should be reported to our clinical team immediately, as dose adjustments or additional supportive measures may be appropriate.

When to Contact Your Prescriber

Whilst mild side effects are expected during the Wegovy starter dose UK phase, certain symptoms warrant immediate clinical review. Contact our team if you experience severe abdominal pain (which may indicate pancreatitis), persistent vomiting preventing fluid intake, signs of allergic reaction such as rash or breathing difficulty, or visual changes. Our pharmacists are available on (+44) 116 4646009 during business hours, and all patients receive written guidance on managing side effects and recognising warning signs that require urgent assessment.

Progressing Beyond the Wegovy Starter Dose UK

After completing the four-week Wegovy starter dose UK phase, patients progress to the 0.5mg dose for the next four weeks, provided the starter dose was well-tolerated. This stepwise escalation continues monthly through 1mg, 1.7mg, and ultimately 2.4mg, which is the maintenance dose shown in clinical trials to deliver optimal weight loss outcomes. Each dose increase should only occur after completing the full four weeks at the current dose level.

At Cured Pharmacy, we provide seamless prescription continuity throughout your entire Wegovy journey. After your initial starter dose prescription, our clinical team conducts regular follow-up assessments to monitor your progress, review any side effects, and authorise progression to the next dose tier. This ongoing clinical oversight ensures you receive personalised support whilst maintaining the structured escalation protocol that underpins Wegovy's efficacy and safety profile [6].

Some patients may require an extended period at a particular dose if they experience tolerability issues or wish to consolidate weight loss before escalating. Our prescribers work collaboratively with each patient to determine the optimal escalation timeline based on individual response, side effect profile, and weight loss goals. The flexibility to adjust the pace of dose increases, whilst maintaining the overall structure, is one advantage of receiving Wegovy through a dedicated pharmacy clinical team rather than a one-size-fits-all approach.

Scientific References

1. Novo Nordisk. (2023). Wegovy (semaglutide) injection 2.4mg: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 15 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
4. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. [accessed 15 August 2026]
5. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 15 August 2026]
6. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. NICE. [accessed 15 August 2026]
7. Wilding, J. P. H., Batterham, R. L., Davies, M., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564. [accessed 15 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.